



GSK Influenza Update


Leonard Friedland, MD
Vice President, Scientific Affairs and Public Health, Vaccines

GSK's Global & US Commitment to Influenza Canada, Germany, Belgium, US Manufacturing



Importance of Timely Delivery to Customer

Improving GSK's Ability to Supply Seasonal Influenza Vaccine




2015-16 GSK US Supply of Influenza Vaccine

Fluarix QIV Prefilled Syringe and FluLaval QIV Multi-dose Vial



- ✓ QIV Only for the 2015-16 Season
- ✓ 32-38 million doses planned for the US
 - ✓ 30% INCREASE in supply capacity over 2014-15
 - ✓ Final quantities will be based on demand & production capabilities
- ✓ On TRACK to start shipment in early August



Commitment to U.S. Public Health

Show Value of Public-Private Partnership



CENTER FOR INNOVATION
IN ADVANCED DEVELOPMENT & MANUFACTURING
TEXAS A&M HEALTH SCIENCE CENTER



SHOWS VALUE OF PUBLIC-PRIVATE PARTNERSHIP: Each partner -- the U.S. Government, the State of Texas, Texas A&M and GSK bring specific core competencies and resources to the Texas Center project. We believe this will create synergy, innovation and flexibility on behalf of patients and public health.

GSK Confidential - for internal use only

Global & US Commitment to Patients & Customers

New GSK US Vaccines R&D Center - Rockville, MD



The new US vaccines R&D centre will expand GSK's efforts to discover and develop novel vaccines across a range of pressing public health threats.



Key late stage development programmes, as well as vaccine discovery and new platform technology development will be led from Rockville.